Cargando…

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19

The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gambichler, Thilo, Reuther, Judith, Scheel, Christina H, Becker, Jürgen Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358098/ https://www.ncbi.nlm.nih.gov/pubmed/32611687 http://dx.doi.org/10.1136/jitc-2020-001145

Ejemplares similares

Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection
por: Gambichler, Thilo, et al.
Publicado: (2020)

Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Publicado: (2021)

Expression of DNA mismatch repair proteins in melanoma patients treated with immune checkpoint inhibitors
por: Gambichler, T., et al.
Publicado: (2022)

Prognostic Performance of Inflammatory Biomarkers Based on Complete Blood Counts in COVID-19 Patients
por: Gambichler, Thilo, et al.
Publicado: (2023)

Evans’ syndrome following vaccination with ChAdOx1 nCoV-19 in a patient with new-onset localized scleroderma
por: Gambichler, Thilo, et al.
Publicado: (2022)

Prognostic Potential of the Baseline Pan-Immune-Inflammation Value and Neutrophil/Lymphocyte Ratio in Stage I to III Melanoma Patients
por: Gambichler, Thilo, et al.
Publicado: (2022)

The Antineoplastic Effect of Dimethyl Fumarate on Virus-Negative Merkel Cell Carcinoma Cell Lines: Preliminary Results
por: Gambichler, Thilo, et al.
Publicado: (2023)

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
por: Gambichler, Thilo, et al.
Publicado: (2019)

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
por: Gambichler, Thilo, et al.
Publicado: (2017)

Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19
por: Gatto, Lidia, et al.
Publicado: (2020)

Immune Checkpoints in Viral Infections
por: Cai, Huiming, et al.
Publicado: (2020)

The pan-immune-inflammation value and systemic immune-inflammation index in advanced melanoma patients under immunotherapy
por: Susok, L., et al.
Publicado: (2022)

Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
por: Olivares-Hernández, Alejandro, et al.
Publicado: (2021)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Immune checkpoint inhibitors in cancer patients with COVID-19
por: Pan, Yun, et al.
Publicado: (2023)

Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma
por: Gambichler, T., et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

COVID‐19, varying genetic resistance to viral disease and immune tolerance checkpoints
por: Goodnow, Christopher C
Publicado: (2020)

The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression
por: Srinivas, Nalini, et al.
Publicado: (2023)

NSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?
por: Capuano, Annalisa, et al.
Publicado: (2020)

Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection?
por: Kattan, Joseph, et al.
Publicado: (2020)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer
por: Tan, Ruoding, et al.
Publicado: (2022)

Undifferentiated pleomorphic sarcoma of the breast with neoplastic fever: case report and genomic characterization
por: Gambichler, Thilo, et al.
Publicado: (2022)

Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor
por: Chong, Kah-Meng, et al.
Publicado: (2022)

Model for End-Stage Liver Disease Correlates with Disease Relapse and Death of Patients with Merkel Cell Carcinoma
por: Gambichler, Thilo, et al.
Publicado: (2023)

Therapeutic Potential of Alpha-Lipoic Acid in Viral Infections, including COVID-19
por: Dragomanova, Stela, et al.
Publicado: (2021)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Neurotoxicity
por: Zhao, Zhiyi, et al.
Publicado: (2021)

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
por: Shah, Neil J., et al.
Publicado: (2019)

Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic
por: Chang, Hsu-Liang, et al.
Publicado: (2020)

COVID-19 VERSUS IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS: A CLINICAL DILEMMA
por: Dewaswala, Nakeya, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
por: Gubbi, Sriram, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tca3muf0sd8fg7oj4rum7eu0hg